News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
413,749 Results
Type
Article (27297)
Company Profile (154)
Press Release (386298)
Section
Business (127400)
Career Advice (1240)
Deals (22878)
Drug Delivery (94)
Drug Development (60724)
Employer Resources (122)
FDA (9681)
Job Trends (9579)
News (224841)
Policy (20914)
Tag
Academia (1515)
Alliances (33424)
Alzheimer's disease (776)
Approvals (9631)
Artificial intelligence (91)
Bankruptcy (198)
Best Places to Work (7070)
Biosimilars (69)
Biotechnology (71)
Breast cancer (67)
Cancer (596)
Cardiovascular disease (62)
Career advice (1017)
Cell therapy (100)
Clinical research (49307)
Collaboration (196)
Compensation (64)
COVID-19 (1698)
Data (600)
Diabetes (109)
Diagnostics (2798)
Drug pricing (92)
Earnings (44895)
Employer resources (111)
Events (58805)
Executive appointments (186)
FDA (9951)
Funding (165)
Gene therapy (105)
GLP-1 (532)
Government (2438)
Healthcare (9488)
Infectious disease (1757)
Inflammatory bowel disease (84)
Interviews (188)
IPO (9159)
Job creations (2720)
Job search strategy (920)
Layoffs (282)
Legal (4899)
Lung cancer (109)
Manufacturing (120)
Medical device (4542)
Medtech (4546)
Mergers & acquisitions (13748)
Metabolic disorders (345)
Neuroscience (957)
NextGen Class of 2024 (3700)
Non-profit (2156)
Northern California (668)
Obesity (217)
Opinion (182)
Patents (70)
People (39978)
Pharmaceutical (77)
Phase I (14711)
Phase II (21162)
Phase III (17171)
Pipeline (160)
Policy (67)
Postmarket research (1938)
Preclinical (5416)
Radiopharmaceuticals (174)
Rare diseases (135)
Real estate (3818)
Regulatory (14398)
Research institute (1445)
Resumes & cover letters (185)
Southern California (630)
Startups (2521)
United States (6602)
Vaccines (369)
Weight loss (188)
Date
Today (135)
Last 7 days (501)
Last 30 days (1807)
Last 365 days (21938)
2024 (18696)
2023 (24185)
2022 (32035)
2021 (33981)
2020 (32296)
2019 (27754)
2018 (21425)
2017 (21676)
2016 (20770)
2015 (24334)
2014 (18597)
2013 (15344)
2012 (16580)
2011 (17179)
2010 (15516)
Location
Africa (526)
Arizona (69)
Asia (29464)
Australia (4293)
California (1526)
Canada (776)
China (145)
Colorado (65)
Connecticut (65)
Europe (63956)
Florida (214)
Illinois (182)
Indiana (129)
Kansas (61)
Maryland (288)
Massachusetts (1258)
Minnesota (106)
New Jersey (577)
New York (504)
North Carolina (400)
Northern California (668)
Ohio (69)
Pennsylvania (411)
South America (781)
Southern California (630)
Texas (208)
Washington State (202)
413,749 Results for "tanner pharma group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bio NC
ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO® (temozolomide) in European Countries
ORPHELIA Pharma and Tanner Pharma Group have signed an exclusive agreement to manage the supply and distribution of Ped-TMZ, also known as KIMOZO®, to meet the special demands which may come from physicians for this unapproved pediatric form of temozolomide.
April 18, 2023
·
2 min read
LSL Pharma Group Completes the Acquisition of Virage Santé
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the completion of the acquisition of Virage Santé, a company specializing in the manufacturing and marketing of natural health products, based in Lévis, Quebec.
June 18, 2024
·
3 min read
Business
LSL Pharma Group Announces Voting Results of Its Annual and Special Meeting of Shareholders
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, is pleased to announce the results of its annual and special meeting of shareholders held in Montréal, Québec.
June 28, 2024
·
3 min read
Business
Envision Pharma Group Announces the Appointment of Alistair Macdonald to Board of Directors
Envision Pharma Group announced the appointment of Alistair Macdonald to the Envision Board of Directors.
May 8, 2024
·
2 min read
Business
LSL Pharma Group Reports Record Revenues and Margins for the First Quarter 2024
LSL PHARMA GROUP INC. (TSXV: LSL) (the “Corporation” or “LSL Pharma "), a Canadian integrated pharmaceutical company, today reported its financial results for the first quarter of fiscal year 2024 ended on March 31, 2024.
May 30, 2024
·
7 min read
LSL Pharma Group Secures $1.5 Million as the First Closing of Its Non-Brokered Private Placement
LSL PHARMA GROUP INC. announced that it has met the closing conditions of a non-brokered private placement for $1,5 million representing the first closing of the private placement financing announced on June 5, 2024.
June 27, 2024
·
5 min read
Business
LSL Pharma Group Announces the Addition of New Members to Its Board of Directors
LSL PHARMA GROUP INC. announced the appointment of Diane Beaudry and Mario Paradis to its Board of Directors.
April 23, 2024
·
4 min read
Deals
LSL Pharma Group Enters Into Binding Agreement to Acquire Quebec Competitor
LSL PHARMA GROUP INC. is pleased to announce that it has entered into a binding Letter of Intent to acquire profitable privately held, Quebec-based competing contract drug manufacturer specialized in the formulation, production, and marketing of natural products .
May 6, 2024
·
3 min read
LSL Pharma Group Announces Listing of Convertible Redeemable Debentures on the TSXV
LSL PHARMA GROUP INC. is pleased to announce that the Convertible Unsecured Redeemable Debentures issued pursuant to a $3.288 million brokered private placement completed in tranches on November 1, 2023 and December 8, 2023 have been approved for listing on the TSXV under the symbol “LSL.DB” and will begin trading on May 24, 2024.
May 22, 2024
·
3 min read
Business
LSL Pharma Group Reports Its Fourth Quarter and Year-End 2023 Results and Highlights
LSL PHARMA GROUP INC. reported its financial results for the year-ended December 31, 2023.
April 30, 2024
·
10 min read
1 of 41,375
Next
